Articles
-
Feb 23, 2024 |
ejso.com | Mina Sarofim |Anthony Gill |Keshani De Silva |Amir Ashrafizadeh |Justin Evans |Stephen Clarke | +4 more
Questionable risk-benefit ratio of adjuvant therapy in stage II colorectal cancer due to the lack of validated stratification factors for the selection of patients
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →